Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, today announced that it has executed a definitive agreement for a $25 million credit facility with Deutsche Bank AG.
Spanish healthcare company Grifols has agreed to acquire the remaining stake in Alkahest, a Silicon Valley-based biopharma company, for $146m.
This fiber optic measuring system is based on the backscattered light principle and consequently provides the highest possible performance from low/medium turbidities right through to high suspended particle concentrations.
Kite, a Gilead Company and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML).
Gilead Sciences has signed an exclusive licensing deal worth up to $805m with Jounce Therapeutics for the latter's immunotherapy candidate JTX-1811.
Ionis Pharmaceuticals has signed an agreement to purchase remaining stake in US-based biopharmaceutical company Akcea Therapeutics in a deal valued at around $500m.
BeiGene has entered into an exclusive licence agreement with Singlomics (Beijing DanXu) Biopharmaceuticals for neutralising Covid-19 antibodies.
Engitix, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).
Sinovac Biotech, a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Hainan, China with PT Bio Farma, a leading biopharmaceutical company in Indonesia, for the supply, local production and technology licensing in respect of the CoronaVac, Sinovac’s inactivated vaccine candidate against Covid-19.
Acadia Pharmaceuticals has added novel pain programme to its portfolio with the acquisition of clinical-stage biotechnology company CerSci Therapeutics.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.